Ii-Key/MHC class II epitope hybrids: a strategy that enhances MHC class II epitope loading to create more potent peptide vaccines
Authors:
- Xueqing LuXLXueqing Lu
- Catherine E BlackwellCBCatherine E Blackwell
- Eric von HofeEHEric von Hofe
- Robert E HumphreysRHRobert E Humphreys
- Minzhen XuMXMinzhen Xu
- 22 November 2006
- journal article
- review article
- Published by Taylor & Francis in Expert Opinion on Biological Therapy
- Vol. 6 (12) , 1311-1321
Abstract
Life-threatening diseases, such as cancer and pandemic influenza, demand new efforts towards effective vaccine design. Peptides represent a simple, safe and adaptable basis for vaccine development; however, the potency of peptide vaccines is insufficient in most cases for significant therapeutic efficacy. Several methods, such as Ligand Epitope Antigen Presentation System and ISCOMATRIX, have been developed to enhance the potency of peptide vaccines. One way of increasing the loading of MHC class II peptides occurs through the use of Ii-Key technology. Ii-Key (LRMK), a portion of the MHC class II-associated invariant chain (Ii), facilitates the direct loading of epitopes to the MHC class II molecule groove. Linking the Ii-Key moiety via a simple polymethylene bridge to an MHC class II epitope, to generate an Ii-Key/MHC class II epitope hybrid, greatly enhances the vaccine potency of the tethered epitope. The combination of such Ii-Key/MHC class II epitope hybrids with MHC class I epitope-containing peptides might generate a potent peptide vaccine for malignancies and infectious diseases. The Ii-Key hybrid technology is compared with other methods that enhance the potency of a peptide vaccine.Keywords
This publication has 79 references indexed in Scilit:
- Functionally divergent T lymphocyte responses induced by modification of a self-peptide from a tumor-associated antigenClinical Immunology, 2005
- Cognate CD4+ T cell licensing of dendritic cells in CD8+ T cell immunityNature Immunology, 2004
- Activation of Tumor-specific CD4+ T Lymphocytes by Major Histocompatibility Complex Class II Tumor Cell VaccinesCancer Research, 2004
- Complementary Role of CD4+ T Cells and Secondary Lymphoid Tissues for Cross-presentation of Tumor Antigen to CD8+ T CellsJournal of Experimental Medicine, 2003
- The N-Terminal Flanking Region of the Invariant Chain Peptide Augments the Immunogenicity of a Cryptic “Self” Epitope from a Tumor-Associated AntigenClinical Immunology, 2001
- A Three-Step Kinetic Mechanism for Peptide Binding to MHC Class II ProteinsBiochemistry, 2000
- Pan DR binding sequence provides T-cell help for induction of protective antibodies against Plasmodium yoelii sporozoitesVaccine, 1999
- Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative TumorsJournal of Experimental Medicine, 1998
- MHC class II-associated invariant chain contains a sorting signal for endosomal compartmentsCell, 1990
- Inhibition by leupeptin and antipain of the intracellular proteolysis of IiHuman Immunology, 1989